Homologous recombination repair deficiency (HRD) is associated with response to poly-ADP-ribose polymerase inhibition (PARPi) therapy in advanced ovarian cancer. In combination with CGP, these analyses allow clinicians to maximize clinical information so that patients are matched with approved therapies or enrolled in relevant clinical trials. 

In this workshop, a pathologist and laboratory director will discuss the impact of implementing a HRD assay at their institution. They will describe the details of implementing the assay, technical considerations for HRD testing, concordance with other HRD assays, and the added value of offering CGP and HRD testing in-house. 

With the increasing number, complexity, and diversity of biomarkers to be tested in support of precision medicine approaches, limited tissue availability and patient health status can be barriers to genomic testing. Liquid biopsies provide an alternative to invasive tissue sample collection to match patients with appropriate therapies based on their genomic profile.  

In this presentation, Roos will discuss the rationale and drivers for the implementation of a CGP liquid biopsy assay to better support molecular testing and therapy matching. She will also highlight real-world evidence that demonstrates the clinical utility of including liquid biopsies in biomarker testing algorithms in both academic and community oncology practices.

Comprehensive Genomic profiling (CGP) is becoming standard of care in oncology. It allows clinicians to maximize clinical information from limited biopsy samples so that patients are matched with approved therapies or enrolled in relevant clinical trials.

In this workshop, our panel will describe the implementation of a CGP assay at their institutions. They will also discuss how flexible automation, sample batching, data analysis and reporting solutions are key to offer CGP testing so that data access and turn-around time can benefit patients.

Learn:

• Reasons to implement and value of a flexible future-proof DNA+RNA CGP assay.
• The impact of reflex CGP testing on testing decision trees and workflow consolidation.
• Value of sample management and genomic literacy for oncologists and molecular tumor boards.